Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors

Journal of the American College of Cardiology

Volumn 26, Issue 7, 1995, Pages 1665-1671

  Kleiman, Neal S ^a,c   Raizner, Albert E ^a,c   Jordan, Robert ^a,c   Wang, Ann L ^a,c   Norton, Daniel ^a,c   Mace, Kenneth F ^a,c   Joshi, Alaknanda ^a,c   Coller, Barry S ^b,c   Weisman, Harlan F ^a,c  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b CENTOCOR INC   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; MONOCLONAL ANTIBODY; RECEPTOR BLOCKING AGENT; THROMBIN RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DILATATION; FEMALE; HUMAN; HUMAN CELL; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; FEMALE; HUMAN; IMMUNOGLOBULINS, FAB; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGE; OLIGOPEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; RECEPTORS, CELL SURFACE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028807209     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(95)00391-6     Document Type: Article

References (23)

1. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction
2. Collaborative overview of randomized trials of antiplatelet therapy-I prevention of death myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
3. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
4. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization
5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
6. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high risk coronary angioplasty
7. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
8. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation
9. The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation
10. Substituting isoserine for serine in the receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation
11. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents
12. Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies
13. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab following thrombolytic therapy: results of the TAMI 8 pilot study
14. Randomized trial of a GPIIB/IIIa platelet receptor blocker in refractory unstable angina
15. Immunofluorescent localization of adhesive glycoprotein in resting and thrombin-stimulated platelet
16. Resting platelets contain a substantial centrally located pool of glycoprotein IIb–IIIa complex which may be accessible to some but not other extracellular proteins
17. Immunocytochemical evidence for the translocation of a-granule membrane glycoprotein II/IIIa (integrin aII/B3) of human platelets to the surface membrane during the release reaction
18. Hirudin, heparin, and placebo during deep arterial injury in the pig
19. Increased surface expression of the membrane glycoprotein II/IIIa complex induced by platelet activation, relationship to the binding of fibrinogen and platelet aggregation
20. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease
21. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator
22. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris
23. Comparative real-time effects on platelet adhersion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb/IIIa